AlloVir, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 190.42 million compared to USD 168.71 million a year ago. Basic loss per share from continuing operations was USD 1.83 compared to USD 2.2 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7233 USD | -7.27% |
|
-2.69% | +6.40% |
11/06 | AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc | CI |
13/05 | AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.40% | 88.48M | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |
- Stock Market
- Equities
- ALVR Stock
- News AlloVir, Inc.
- AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023